-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Xetra FrankfurtEURSymbol 22UA-
BioNTechBörse Börse FrankfurtWKNEURSymbol 22UA
-
BioNTechBörse Xetra FrankfurtEURSymbol 22UA
-
BioNTech SE - ADRBörse Börse BerlinEURSymbol 22UA
-
BioNTech SE - ADRBörse Börse MünchenEURSymbol 22UA
-
BIONTECH SE-ADRBörse Börse StuttgartEURSymbol 22UA
-
BIONTECH SE-ADRBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 22UA
-
BIONTECH SE-ADRBörse Börse HamburgEURSymbol 22UA
-
BIONTECH SE-ADRBörse Quotrix System der Börse DüsseldorfEURSymbol 22UA
-
BIONTECH SE-ADRBörse Börse DüsseldorfEURSymbol 22UA
-
BIONTECH SE-ADRBörse Gettex System der Börse MünchenEURSymbol 22UA
-
ISIN US09075V1026 WKN: A2PSR2USDSymbol BNTX
-
BioNTech SE - ADRBörse Bolsa Mexicana de Valore Mexiko-StadtMXNISIN US09075V1026
-
BioNTech SE - ADRBörse Bolsa Mexicana de Valore Mexiko-Stadt
-
BioNTech SEBörse London Stock Exchange
-
Symbol 22UA
Währung
EUR
Börse
Xetra Frankfurt Zeitzone: Europe/Berlin
Firmenname
BioNTech SE
Marktkapitalisierung
26.221.596.672
Mitarbeiter
3.165 (+- 43%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.800 oder 4.530 Mitarbeiter
KGV
-99999.99
EBITDA 0
PEGRatio None
Buchwert None
BioNTech outperformed den DAX um +160 % vom 06.11.2020 bis 30.12.2021
Letzte Communitymeinungen
- 5 User waren zuletzt bullisch
- Im Beta-Tester Jahresendrally Battle 2021
-
SaLyn
14.09.2021
-
Karamellsaus_55
29.08.2021
-
Zockrat
29.08.2021
Ein User hat BioNTech abonniert.
Aktionärsstruktur der BioNTech SE
Portrait der BioNTech Aktie
Das Unternehmen BioNTech SE aus Deutschland beschäftigt 3.165 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Die BioNTech Aktie konnte seit dem 06.11.2020 eine Rendite von 188% erwirtschaften und mit dieser Performance den deutschen Leitindex DAX um 160% outperformed, der im gleichen Zeitraum 27% erwirtschaften konnte.
Mit einem Streubesitz von lediglich 19,7% ist der free float der Aktie vergleichsweise gering. Ein genauerer Blick in die Aktionärsstruktur könnte nützlich sein um den geringen Streubesitz vielleicht aufzuklären.
Das Unternehmen BioNTech SE ist nur in 5 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter VanEck Vectors Biotech ETF gewichtet BioNTech mit 6,85% im ETF.
5 ETFs die in BioNTech investieren
Dir gefallen die Informationen zu BioNTech?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu BioNTech?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu BioNTech?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu BioNTech?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
358 News & Informationen zur BioNTech Aktie
FDA is expected to give full approval of Pfizer COVID-19 vaccine next week
The Food and Drug Administration is expected next week to grant full approval of the COVID-19 vaccine from Pfizer Inc. and partner BioNTech SE, according to…
U.S. FDA aims to give full approval to Pfizer vaccine on Monday
U.S. FDA aims to give full approval to Pfizer vaccine on Monday – NYT
As Covid-19 Boosters Loom, Pfizer and Moderna Expect to See Billions More in Sales
Vaccine makers Pfizer Inc. and Moderna Inc. are on track to notch billions more in sales than previously expected, as new booster-shot strategies and concerns about the Delta variant push demand, and the companies raise prices in the U.S. and elsewhere.
Should Investors Follow Private Equity into Life Sciences?
GuruFocus Article or News written by Barry Cohen and the topic is about: Bain Capital has put about $4 billion into industry funds since 2017
As covid-19 boosters loom, Pfizer and Moderna expected to see billions more in sales
The spread of the Delta variant is increasing demand for messenger RNA vaccines and boosters, while the companies raise prices
Treasury yields fall as growth worries pressure stocks
Treasury yields fall Thursday, pressured by worries about the spread of the delta variant of the coronavirus that causes COVID-19 on the economic outlook…
Biden’s Booster Shot Push Raises Concerns Among Health Experts
(Bloomberg) — The White House’s plan to begin offering booster shots next month to almost all vaccinated U.S. adults is raising concerns among health experts that the administration is rushing ahead without enough data and regulatory oversight.
On Wednesday as expected, officials from the U.S.
S&P 500 Stumbles as Fed Signals Tapering This Year By Investing.com
S&P 500 Stumbles as Fed Signals Tapering This Year
Biden to mandate COVID vaccines for nursing home workers: reports
President Joe Biden is due to give a speech on Wednesday as his administration rolls out its plan to provide booster shots of COVID-19 vaccines.
S&P 500 in Holding Pattern Ahead of Fed Minutes By Investing.com
S&P 500 in Holding Pattern Ahead of Fed Minutes
Here’s Why You Should Definitely Invest in BioNTech SE (BNTX)
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2021 investor letter – a copy of which can be downloaded here.
Moderna cements lead as S&P’s top stock of 2021
Moderna is the star stock of 2021 maintaining its position as the S&P 500’s top performer.
Parametrica Management Ltd Buys BioNTech SE, StoneCo, Tilray Inc, Sells Tencent Music Entertainment Group, JD.com Inc, Norwegian Cruise Line Holdings
GuruFocus Article or News written by insider and the topic is about:
No data shows need for booster vaccines presently: Dr Gagandeep Kang
Read more about No data shows need for booster vaccines presently: Dr Gagandeep Kang on Business Standard. According to Dr Kang, whether people will have more antibodies or be better protected with the booster dose is still not known
If you have taken a Pfizer Covid-19 vaccine – here’s what you should know about a third ‘booster’ shot
Pharmaceutical companies Pfizer and BioNTech have submitted data to the US Food and Drug Administration (FDA) to support the evaluation of a third booster shot…
HK Raises Quarantine Time; New Zealand Local Case: Virus Update
(Bloomberg) — Hong Kong will hike quarantine for medium-risk places to 14 days to curb the spread of the virus. Business groups in the city are already…
Pfizer, BioNTech Submit COVID-19 Booster Vaccine Data To FDA
(RTTNews) – Pfizer Inc. (PFE) and BioNTech SE (BNTX) have submitted phase 1 data to the U.S. Food and Drug Administration to support the evaluatio…
Pfizer submits initial data for COVID-19 vaccine booster authorization
They said the third dose showed significantly higher neutralizing antibodies against the initial SARS-CoV-2 virus compared to the two doses as well as against the Beta and the highly infectious Delta variants.
Pfizer: The Rally Is Far From Finished
GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.
Pfizer: The Rally Is Far From Finished
GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.
Pfizer: The Rally Is Far From Finished
GuruFocus Article or News written by Nathan Parsh and the topic is about: The stock is up 16% since the earnings release, but could see double-digit returns on a modest multiple expansion.
Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster
Data from an early-stage study shows that a third vaccine dose offers a higher level of protection, the companies say.
Pfizer submits initial data for COVID-19 vaccine booster authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a…
Pfizer, BioNTech File Initial Data to FDA to Support Covid-19 Vaccine Booster Dose
By Colin Kellaher
Pfizer Inc. and BioNTech SE on Monday said they have submitted Phase 1 data to the U.S. Food and Drug Administration to support the evaluation of a booster dose of their… | August 16, 2021
Pfizer, BioNtech submit data to FDA for Covid vaccine booster authorisation
The data will also be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks, the drugmakers said
Pfizer And BioNTech Announce Submission Of Initial Data To U.S. FDA To Support Booster Dose Of COVID-19 Vaccine
Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile
CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates
Shares of CureVac N.V. undefined gained 0.4% in morning trading Monday, but bucked the selloff in the biotechnology sector and the broader stock market,…
„Immer mehr VC-Fonds verpflichten sich auf die Einhaltung von Nachhaltigkeitskriterien“
BioNTech Downtick Continues
BioNTech SE (BNTX) shares are sliding on Monday morning trade continuing a fall since August 13. There were no corporate announcements from the company today to impact the stock movement.
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to domin…
The world may never reach herd immunity against Covid-19
As Covid-19 surged last year, governments worldwide touted the hope of “herd immunity,” a promised land where the virus stopped spreading exponentially…
Consumer sentiment sinks to height of COVID-19 levels
Consumers are growing more worried that the pandemic will return and derail the progress made with vaccines and reopenings.
FDA Authorized Covid Booster Shot For Those With Weakened Immune Systems
The Food and Drug Administration approved COVID-19 vaccine booster shots for people with weakened immune systems, according to CNBC.
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
FDA Authorizes Covid-19 Boosters for Certain Immunocompromised
The agency cleared giving a third dose of a vaccine from Pfizer or Moderna to certain immunocompromised people, likely the launch of broader efforts to better protect against evasive variants like Delta.
BioNTech SE (BNTX): From Speculative To Portfolio Must-Have (Part 1)
Brief review of the BioNTech vision. Extensive review of the BioNTech competitive positioning. Extensive evaluation of the COVID-19 vaccine market now and into the future.
Covid-19 vaccine scammers target authorities in dozens of countries including Italy and Colombia
Criminal groups and individuals have proposed contracts for millions of dollars to officials; vaccine makers say they don’t use intermediaries and will sell only directly to governments
BioNTech-Nebenwirkungen: Börse reagiert nach Prüfung der EMA
Auf diese Meldung reagierten die Märkte sofort: Die EU-Arzneimittelagentur EMA untersucht mögliche Begleiterscheinungen der Impfungen mit…
Stocks little changed ahead of PPI, weekly jobless claims
U.S. stock indexes were pointing to small gains at the opening bell ahead of key economic data.